ALNY
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
Alnylam Pharmaceuticals, Inc. (ALNY) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (F). The rating has held at C- for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.0) | D+ (1.8) | A- (3.9) | C- (2.0) | F (0.0) | C- (2.1) |
| 2026-11-10 | B- (3.0) | D+ (1.8) | A- (3.9) | C- (2.0) | F (0.0) | C- (2.1) |
| 2026-11-03 | B- (3.0) | D+ (1.8) | A- (3.9) | C- (1.9) | F (0.0) | C- (2.1) |
| 2026-10-27 | C+ (2.5) | B (3.3) | A- (4.0) | C- (1.9) | A+ (5.0) | B (3.3) |
| 2026-10-20 | C (2.5) | B (3.3) | A- (4.0) | C- (2.0) | A+ (5.0) | B (3.3) |